Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Makers of brand-name drugs called out by the Trump administration for potentially stalling generic competition have hiked their prices by double-digit percentages since 2012 and cost Medicare and Medicaid nearly $12 billion in 2016, a Kaiser Health News analysis has found.
Researchers from the Wolfson Faculty of Chemical Engineering at the Technion-Israel Institute of Technology have developed an integrated system for early diagnosis of diseases using wearable monitors.
A new and early target for treating pulmonary hypertension appears to be an enzyme that's normally key to energy production but destructive in the face of this high blood pressure inside your lungs.
In a recent study, scientists found that eliminating the FoxM1 gene could improve outcomes for patients with pulmonary hypertension.
In the current issue of Cardiovascular Innovations and Applications (Volume 2, Number 4, 2018, pp 439-446(8); DOI: https://doi.org/10.15212/CVIA.2017.0027, researchers Yee-Ping Sun and Patrick T. O'Gara, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA present a case study of management of rheumatic mitral regurgitation in a woman contemplating pregnancy.
Working with cells that line the innermost layer of the blood vessels, Johns Hopkins investigators say they have made a leap forward in understanding the underlying biology behind pulmonary hypertension, a dangerous type of high blood pressure in lungs that ultimately leads to right heart failure and death.
A small, daily dose of Viagra significantly reduces colorectal cancer risk in an animal model that is genetically predetermined to have the third leading cause of cancer death, scientists report.
Some heart patients haven't yet been able to access the growing trend toward minimally invasive procedures. A new clinical trial, though, makes a form of mitral valve repair an option without an open-heart surgery.
Physician-scientists from the University of Alabama at Birmingham using "big-data" recently summarized in the Journal of the American Heart Association the prevalence of cardiovascular manifestations, rates of defibrillator placement and predictors of in-hospital mortality in sarcoidosis -; a disorder that affects multiple organs.
The Transplant Institute at NYU Langone Health has launched a new lung transplant program, the third program of its kind in the greater New York City area, expanding regional access to this specialized level of care.
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart and Lung Research in Bad Nauheim and the German Center for Lung Research found after examining more than 500 patients.
Use of liver organs from selected hepatitis C positive donors should be considered due to modest risk of hepatitis C transmission and the availability of safe and effective direct‐acting antiviral therapies, according to research presented this week at The Liver Meeting -; held by the American Association for the Study of Liver Diseases.
A team of Cleveland Clinic researchers found that a common heart disease medication, beta blockers, may help treat pulmonary arterial hypertension (PAH), a debilitating lung disease.
With over 1,400 products in active development, the innovation pipeline for cardiovascular disease (CVD) is extensive, with four key CVD indications – hypertension, heart failure, dyslipidemia and thrombosis – now accounting for around half of all pipeline innovation, according to GBI Research, a recognized leader in providing business information and analytics.
Mount Sinai has partnered with Theragene Pharmaceuticals, Inc. to advance a novel airway-delivered gene therapy for treating pulmonary hypertension (PH), a form of high blood pressure in blood vessels in the lungs that is linked to heart failure.
The first app and score to determine the one-year risk of a liver transplant patient dying or being hospitalized for a heart attack or other cardiovascular complication has been developed by Northwestern Medicine scientists.
New treatments have extended the lives of many lung cancer patients. However, even better than treating lung cancer would be preventing it from developing in the first place.
Urinary incontinence in women is common, with almost 50% of adult women experiencing leakage at least occasionally. Genetic or heritable factors are known to contribute to half of all cases, but until now studies had failed to identify the genetic variants associated with the condition.
In a new study, CT-measured vascular pruning – the diminution of distal pulmonary blood vessels (vessels on the outer edges of the lungs) – was associated with increased risk of death in smokers without chronic obstructive pulmonary disease.
A study of more than 80,000 women with heart disease from 2003 to 2012 reveals that the prevalence of women with heart disease delivering babies increased by 24 percent over that 10-year period.